Former executive of Taro Pharmaceutical indicted in U.S. for price-fixing

WASHINGTON (Reuters) – A former sales and marketing executive of Taro Pharmaceutical Industries Ltd, Ara Aprahamian, has been indicted for price-fixing and bid-rigging, among other charges.

The Justice Department said that Aprahamian was indicted on Tuesday for participating in two conspiracies to fix generic drug prices between 2013 and 2015.

Bob Gage, a lawyer for Aprahamian, said that he looked forward to his day in court. “We have absolute confidence that once all the facts are brought to light Mr. Aprahamian will be proven innocent,” Gage said.

Aprahamian was previously vice president of sales at Taro, according to the Connecticut’s Office of Attorney General. The Justice Department did not respond to questions about Aprahamian’s employment.

He is also charged with lying to an FBI agent when he denied that he had spoken to a competitor about pricing.

The issue of drug pricing has become a hot one amid reports that some drugs, including some on the markets for decades, have seen their prices increase sharply.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.